Market open
Organogenesis/$ORGO
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Organogenesis
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced wound care, surgical and sports medicine markets. Its product category includes Advanced Wound Care and Surgical and Sports Medicine. It has single operating segment which has regenerative medicine. The company generates maximum revenue from Advanced Wound Care products. Some of its products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, Dermagraft and others.
Ticker
$ORGO
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
862
Website
Organogenesis Metrics
BasicAdvanced
$432M
Market cap
-
P/E ratio
-$0.13
EPS
1.65
Beta
-
Dividend rate
Price and volume
Market cap
$432M
Beta
1.65
52-week high
$4.71
52-week low
$1.96
Average daily volume
409K
Financial strength
Current ratio
2.732
Quick ratio
2.285
Long term debt to equity
35.168
Total debt to equity
42.834
Interest coverage (TTM)
6.66%
Management effectiveness
Return on assets (TTM)
1.94%
Return on equity (TTM)
-6.19%
Valuation
Price to revenue (TTM)
0.958
Price to book
1.64
Price to tangible book (TTM)
1.96
Price to free cash flow (TTM)
50.416
Growth
Revenue change (TTM)
-1.96%
Earnings per share change (TTM)
-263.80%
3-year revenue growth (CAGR)
1.14%
3-year earnings per share growth (CAGR)
-38.93%
What the Analysts think about Organogenesis
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Organogenesis stock.
Organogenesis Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Organogenesis Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Organogenesis News
AllArticlesVideos
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024
GlobeNewsWire·3 weeks ago
Organogenesis Announces Publication of Randomized Clinical Trial Results Demonstrating the Safety and Efficacy of NuShield for Diabetic Foot Ulcers
GlobeNewsWire·1 month ago
Organogenesis Holdings Inc. to Participate in Upcoming Investor Conferences in September
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Organogenesis stock?
Organogenesis (ORGO) has a market cap of $432M as of November 08, 2024.
What is the P/E ratio for Organogenesis stock?
The price to earnings (P/E) ratio for Organogenesis (ORGO) stock is 0 as of November 08, 2024.
Does Organogenesis stock pay dividends?
No, Organogenesis (ORGO) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next Organogenesis dividend payment date?
Organogenesis (ORGO) stock does not pay dividends to its shareholders.
What is the beta indicator for Organogenesis?
Organogenesis (ORGO) has a beta rating of 1.65. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.